Characterisation of levofloxacin-resistant clinical isolates of Streptococcus pyogenes in Bilbao, Spain

被引：9

作者：

Alonso, Rodrigo

Mateo, Estibaliz

Ezpeleta, Guillermo

Cisternaa, Ramon

机构：

[1] Univ Basque Country, Fac Farm, Dept Inmunol Microbiol & Parasitol, Vitoria 01006, Spain

[2] Hosp Basurto, Microbiol Serv, Bilbao 48013, Spain

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2007年 / 30卷 / 02期

关键词：

fluoroquinolone; resistance; parC; gyrA; Streptococcus pyogenes;

D O I：

10.1016/j.ijantimicag.2007.04.001

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The resistance mechanisms and clonal relationship were determined for two Streptococcus pyogenes isolates with high-level resistance to levofloxacin as well as to other fluoroquinolones. DNA amplification and sequencing revealed a serine-81 -> phenylalanine substitution in GyrA and a double substitution in ParC of serine-79 -> phenylalanine and aspartic acid-91 -> asparagine. Pulsed-field gel electrophoresis analysis and emm typing determined that both isolates were emm type 28 and were genetically indistinguishable. (c) 2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

引用

收藏

页码：183 / 185

页数：3

相关论文

共 17 条

[1] Streptococcus pyogenes pharyngeal isolates with reduced susceptibility to ciprofloxacin in Spain:: Mechanisms of resistance and clonal diversity [J].

Albertí, S ;

Cortés, G ;

García-Rey, C ;

Rubio, C ;

Baquero, F ;

García-Rodríguez, JA ;

Bouza, E ;

Aguilar, L .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (01) :418-420

[2] parC mutation conferring ciprofloxacin resistance in Streptococcus pyogenes BM4513 [J].

Alonso, R ;

Galimand, M ;

Courvalin, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (11) :3686-3687

[3] Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae:: Contributions of type II topoisomerase mutations and efflux to levels of resistance [J].

Bast, DJ ;

Low, DE ;

Duncan, CL ;

Kilburn, L ;

Mandell, LA ;

Davidson, RJ ;

de Azavedo, JCS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :3049-3054

[4] Genetic relatedness and superantigen expression in group A streptococcus serotype MZ isolates from patients with severe and nonsevere invasive diseases [J].

Chatellier, S ;

Ihendyane, N ;

Kansal, RG ;

Khambaty, F ;

Basma, H ;

Norrby-Teglund, A ;

Low, DE ;

McGeer, A ;

Kotb, M .

INFECTION AND IMMUNITY, 2000, 68 (06) :3523-3534

[5]

Clinical and Laboratory Standards Institute, 2005, PERF STAND ANT SUSC

[6] Fluoroquinolone resistance associated with target mutations and active efflux in orophalyngeal colonizing isolates of viridans group streptococci [J].

Guerin, F ;

Varon, E ;

Hoï, AB ;

Gutmann, L ;

Podglajen, I .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2197-2200

[7] Detection of multiple macrolide- and lincosamide-resistant strains of Streptococcus pyogenes from patients in the Boston area [J].

Hasenbein, ME ;

Warner, JE ;

Lambert, KG ;

Cole, SE ;

Onderdonk, AB ;

McAdam, AJ .

JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (04) :1559-1563

[8] Clonal spread of fluoroquinolone non-susceptible Streptococcus pyogenes [J].

Malhotra-Kumar, S ;

Lammens, C ;

Chapelle, S ;

Mallentjer, C ;

Weyler, J ;

Goossens, H .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (03) :320-325

[9] Epidemiology of invasive group A Streptococcus disease in the United States, 1995-1999 [J].

O'Brien, KL ;

Beall, B ;

Barrett, NL ;

Cieslak, PR ;

Reingold, A ;

Farley, MM ;

Danila, R ;

Zell, ER ;

Facklam, R ;

Schwartz, B ;

Schuchat, A .

CLINICAL INFECTIOUS DISEASES, 2002, 35 (03) :268-276

[10] Intrinsic reduced susceptibility of serotype 6 Streptococcus pyogenes to fluoroquinolone antibiotics [J].

Orscheln, RC ;

Johnson, DR ;

Olson, SM ;

Presti, RM ;

Martin, JM ;

Kaplan, EL ;

Storch, GA .

JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (08) :1272-1279